SUMMARY

A LOT OF GOOD NEW IS ALREADY PRICED IN

### Authors

JULIEN HOLTZ jholtz@pictet.com

LUC LUYET Iluyet@pictet.com

### Brazil's GDP growth outlook is improving, with expectations for 2021 above 5%.

- > Having proved resilient during the second covid wave, the acceleration of the vaccination campaign should allow a steady reopening of the Brazilian economy.
- > Encouraging data has been accompanied by inflationary pressures, prompting the central bank (BCB) to react swiftly and the market to price in an extra 200bps of rate hikes over the next three months.
- > Political noise has been rising of late, with allegations of corruption emerging around contracts to supply covid vaccines. We expect the controversy to abate in the coming weeks.
- > While rising growth prospects and cheap valuations make the current optimism around Brazilian equities understandable, we believe most of the good news is already priced in.
- > Unexcited by the outlook for Brazilian equities for the rest of this year, we are downgrading our position to neutral despite a slight rise in our year-end target for the Bovespa to 130,000.
- > The Brazilian real performed particularly well in Q2. It rose 13% against the US dollar and easily outperformed other EM currencies, thanks notably to an improving economic outlook and an increasingly hawkish central bank.
- > However, we remain cautious about the real's prospects over the longer term because of Brazil's ongoing fiscal imbalances. Our projections for the USD/BRL rate are BRL5.10 in three months, BRL5.40 in six months and BRL5.70 in 12 months.


## Macroeconomic picture: more growth, more inflation

Brazil's growth outlook is undoubtedly improving. Real GDP growth expectations for 2021 have skyrocketed recently, from around 3.5% just a few weeks ago to about 5% currently. The strong run in oil and industrial metals has provided a significant boost to Brazil's prospects given the country's tight correlation to the commodities cycle. Economic data for the second quarter, including retail sales and services activity, all show favourable dynamics. Industrial production, while soft recently, is nonetheless turning the corner after a difficult first quarter. The rise in purchasing manager indexes (PMI) in June (to 53.9 for the services PMI and 56.4 for the manufacturing PMI) point to further expansion in economic activity.

Incidentally, the second covid-19 wave that reached its apex in March-April showed the Brazilian economy becoming more resilient to the pandemic. This was corroborated by a Brazilian Central Bank (BCB) study that found a loosening of the relationship between economic activity and mobility numbers. In any case, the long and intense second wave is now past its peak, with a big decrease in the mortality rate facilitating further economic reopening.




A LOT OF GOOD NEW IS ALREADY PRICED IN



This positive growth dynamic is reflected in the fiscal balance. Public finances are improving thanks to higher revenues (including transfers from mineral extraction) and lower pandemic-related spending compared to last year. The consolidated government primary balance is expected to be around -2% of GDP in 2021 compared to -9.4% in 2020.

The improved outlook for economic growth has been accompanied by persistent inflationary pressure, which is expected to peak this month and remain above the BCB's target until mid-2022. There is, however, a risk that the drought currently afflicting much of Brazil causes electricity prices to rise further and prevents food inflation from falling. To offset temporary price shocks and keep inflation expectations anchored, the BCB has progressively been moving away from the highly accommodative stance it adopted to deal with the pandemic. This may have consequences for growth in the medium term.

CHART 2: POLICY RATE (SELIC) AND INFLATION (IPCA)





A LOT OF GOOD NEW IS ALREADY PRICED IN

### Whirlwind in a bottle

Of course, Brazil wouldn't be Brazil without eventful politics. Of late, two cases involving negotiations of covid-19 vaccines have placed a question mark over President Jair Bolsonaro's anti-corruption credentials.

First, federal deputy Luis Miranda and his brother, Luis Ricardo Miranda, a civil servant, have claimed the latter came under atypical pressure to sign a BRL1.6 bn contract with India's Bharat Biotech despite several red flags. On Friday, 2 July, supreme court judge Rosa Weber gave the authorities 90 days to collect evidence to determine whether Bolsonaro was guilty of negligence in this case.

In a parallel investigation, Luiz Paulo Dominguetti, a representative of a medical supplies company, accused health ministry officials of requesting a bribe of USD1 per dose while negotiating vaccine supplies from Astrazeneca.

While the news led to protests last weekend and talks of impeachment, the head of the lower house of parliament Arthur Lira, said he currently sees no grounds to launch impeachment procedures. Stories of corruption may therefore impact president Bolsonaro's chances in next year's elections more than the length of his current mandate. Polling firm IPEC's most recent poll indicates that Bolsonaro's approval rating has continued to fall, to 24%, while left-wing populist Luiz Ignacio da Silva (Lula) is scoring twice as high of him in polls related to next year's presidential elections.

In this context, the government has extended emergency aid (dubbed 'coronavouchers') for low-income workers until October 2021. The plan is for these vouchers to be succeeded thereafter by a revamped 'Bolsa Familia' social welfare programme. Pressure from the street and critics from the left of the political spectrum could end up pushing Bolsonaro to act more decisively on this front before next year's presidential election (set to take place in October 2022). As usual in Brazil (and elsewhere), politics and public finances are closely intertwined.

### FIGURE 1: 2022 ELECTIONS - OVERVIEW

Туре	Who?	System
Presidential	President + VP	Two-round system
Gobernatorial	27 Governors & vice- governors (all states)	Two-round system (like Presidential)
Congressional		
Senate	27 seats (1/3 out of 81 total)	Majority voting
Chamber of Deputies	All 513 seats	Open list proportional representation
State Legislature	All seats (24 to 94 depending on state)	Open list proportional representation

FIGURE 2: LIKELY TIMELINE (BASED ON 2018 ELECTIONS)



Source: PWM - AA&MR

Source: PWM - AA&MR




A LOT OF GOOD NEW IS ALREADY PRICED IN

### The red herring of cheap valuations

Optimism around Brazilian equities has been building of late on account of the improving growth outlook, economic reopening, strong earnings growth and cheap valuations. While do not disagree with this upbeat assessment, we believe that most of the good news is already priced in and that the apparent cheapness of Brazilian equities reflects some justified concerns over the medium term.

Since January 2020, earnings expectations (12-month forward, in USD) for the MSCI Brazil have increased by about 32%, whereas the price-to-earnings ratio has contracted by 36%, meaning that Brazilian equities' prices remain about 20% below their pre-pandemic levels in USD terms. However, they have risen by 11% in BRL terms, highlighting the magnitude of Brazilian real (BRL) depreciation.

Part of the reason why Brazilian equities appear so cheap on an absolute basis is the meteoritic growth in expected earnings this year, of the order of 180%. But whereas earnings growth of this magnitude already looks to be priced in, earnings expectations for 2022 are much less rosy, with a contraction in earnings from the materials sector offsetting timid growth in other sectors.



Without any year-over-year growth in earnings expected next year, any rise in future earnings expectations would need to come from analysts' revisions—but these have been slowing in local-currency terms since the end of May. Furthermore, our internal earnings per share (EPS) model based on policy rates and the BRL exchange rate points to stable EPS expectations at best by the end of the year (in USD terms), assuming constant commodity prices. In other terms, we see limited upside potential for earnings upgrades during the rest of the year.



A LOT OF GOOD NEW IS ALREADY PRICED IN

Price movements are therefore more likely to be driven by valuations, which may be affected by the rising political temperature. While CDS spreads suggest markets see political risk as remaining contained further out, current controversies could have an impact on confidence in Brazilian equities in the short term.

We also see a risk that a combination of monetary-policy normalisation and retreating inflation could improve the relative attractiveness of fixed-income instruments over equities, potentially interrupting local mutual funds' rebalancing towards equities.

Given significant political volatility in countries like Chile, Peru, Colombia and Argentina, we feel safer in the larger Latin American countries, which are either benefiting from increasing commodity prices (Brazil) or stimulus measures in the developed world (Mexico). Yet we remain unexcited by the outlook for Brazilian equities for the rest of this year in absolute terms and believe a lot of good news has already been priced in. We are therefore downgrading our position in Brazilian equities to neutral from overweight. However, we have adjusted our year-end target for the Bovespa up slightly to 130,000, reflecting a similar upside to what we expect for EM equities at large.

### Bearish bias on the real

An improving economic outlook, a more hawkish BCB, higher carry, surging terms of trade as well as an improvement in external conditions (robust global risk appetite and fading upward pressure on long-term US interest rates in Q2) have all been boosting the Brazilian real.

The appreciation of the real from roughly BRL5.8 per USD in March to BRL4.9 in June reflects these improvements. With the BCB already signalling a Selic rate of 6.25% at the end of 2021 (compared to 4.25% today), we see monetary policy providing less upside to the currency in the months ahead. While the rise in Brazil's terms of trade might suggest further appreciation of the real, fading momentum in industrial metals prices could also limit the currency's upside potential. External conditions may turn less supportive of EM currencies in general in the months ahead, especially as our central scenario is for a renewed rise in US long-term rates. Higher US rates could weigh on global risk appetite, at least temporarily.

Another key driver of the real is the fiscal outlook. A probable decline in Brazil's debt-to-GDP ratio could help the real. However, the longer-term fiscal outlook remains very challenging. The lack of fiscal consolidation (because of the high political cost) and political uncertainties linked to the 2022 presidential elections could remain an important drag on the real. Overall, while we acknowledge that the real may outperform other EM currencies in the short term, we maintain a bearish bias in the longer term given Brazil's fiscal imbalances. Our projections for the USD/BRL rate are BRL5.10 in three months, BRL5.40 in six months and BRL5.70 in 12 months.



#### DISCLAIMERS

Distributors: Banque Pictet & Cie SA, Route des Acacias 60, 1211 Geneva 73, Switzerland, Pictet & Cie (Europe) S.A., 15A, avenue J. F. Kennedy, L-1855 Luxembourg/B.P. 687, L-2016 Luxembourg.

Banque Pictet & Cie SA is established in Switzerland, exclusively licensed under Swiss Law and therefore subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA).

Pictet & Cie (Europe) SA is established in Luxembourg, authorized and regulated by the Luxembourg Financial Authority, Commission de Surveillance du Secteur Financier.

This marketing communication is not intended for persons who are citizens of, domiciled or resident in, or entities registered in a country or a jurisdiction in which its distribution, publication, provision or use would violate current laws and regulations.

The information, data and analysis furnished in this document are disclosed for information purposes only. They do not amount to any type of recommendation, either general or tailored to the personal circumstances of any person. Unless specifically stated otherwise, all price information is indicative only. No entity of the Pictet Group may be held liable for such information, nor does it constitute an offer or an invitation to buy, sell or subscribe to securities or other financial instruments. The information contained herein is not the result of either financial analysis within the meaning of the Swiss Bankers Association's Directives on the Independence of Financial Research or of investment research for the purposes of the relevant EU MiFID provisions. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy or completeness.

Except for any obligations that any entity of the Pictet Group might have towards the addressee, the addressee should consider the suitability of the transaction to individual objectives and independently assess with a professional advisor the specific financial risks as well as legal, regulatory, credit, tax and accounting consequences.

Furthermore, the information, opinions and estimates in this document reflect an evaluation at the date of initial publication and may be changed without notice. The Pictet Group is not under any obligation to update or keep current the information contained herein. If this document refers to the value and income of one or more securities or financial instruments, it is based on rates from the customary sources of financial information, which may fluctuate. The market value of financial instruments may vary on the basis of economic, financial or political changes, currency fluctuations, the remaining term, market conditions, the volatility and solvency of the issuer or the benchmark issuer. Some investments may not be readily realisable since the market in the securities can be illiquid. Moreover, exchange rates may have a positive or negative effect on the value, the price or the income of the securities or the related investments mentioned in this document. When investing in emerging countries, please note that the political change and economic situation in such countries is significantly less stable than in industrialised countries, and they are much more exposed to the risks of rapid political change and economic setbacks.

Past performance must not be considered an indicator or guarantee of future performance, and the addressees of this document are fully responsible for any investments they make. No express or implied warranty is given as to future performance. Moreover, forecasts are not a reliable indicator of future performance. The content of this document may be read and/or used solely by its addressee. The Pictet Group is not liable for the use, transmission or exploitation of the content of this document. Therefore, any form of reproduction, copying, disclosure, modification and/or publication of the content is under the sole liability of the addressee of this document, and no liability whatsoever will be incurred by the Pictet Group. The addressee of this document agrees to comply with the applicable laws and regulations in the jurisdictions where they use the information reproduced in this document.

This document is issued by Banque Pictet & Cie SA. This publication and its content may be cited, provided that the source is indicated. All rights reserved. Copyright 2021.

Distributor: Pictet & Cie (Europe) S.A., London branch ("Pictet London Branch") This is a marketing communication distributed by Pictet London Branch.

This document sets forth neither a personal recommendation tailored to the needs, objectives and financial situation of any individual or company (investment advice as defined in the Financial Conduct Authority's Handbook of rules and guidance (the "FCA Handbook")), nor the results of investment research within the meaning of the FCA Handbook. Moreover, it does not constitute an offer, or an invitation to buy, sell or subscribe to securities or other financial instruments, nor is it meant as a proposal for the conclusion of any type of agreement. Furthermore, this document should not be considered a suitability report as Pictet London Branch has not received all the necessary information on the recipient to complete its suitability assessment, which covers the recipient's knowledge and experience, tolerance to risk, investment needs and the recipient's ability to absorb financial risk. Should its addressee decide to enter into any transaction in relation to a financial product referred to herein, this will be under the addressee's sole responsibility, and the suitability/appropriateness of the transaction and other financial, legal and tax aspects should be assessed by an expert.

Any information contained in this document is disclosed for information purposes only, and neither the producer nor the distributor can be held liable for any fluctuation in the price of the securities. No express or implied warranty is given as to future performance. The opinions expressed reflect an objective evaluation of information available to the general public, such as rates from customary sources of financial information. The market value of securities mentioned may vary on the basis of economic, financial or political changes, the remaining term, market conditions, the volatility and solvency of the issuer or the benchmark issuer. Moreover, exchange rates may have a positive or negative effect on the value, the price or the income of the securities or the related investments mentioned in this document. It is also expressly noted that forecasts are not a reliable indicator of future performance, while past performance is not a reliable indicator of future results.

You should take investment decisions only when you fully understand the relevant financial product and the risks involved. In particular, you must read the relevant product documentation (such as the issuance programme, final terms, prospectus, simplified prospectus and key (investor) information document), as well as Appendix 4: Risk Warnings Relating to Trading in Financial Instruments of the Terms and Conditions of Pictet London Branch. Structured products are complex financial products and involve a high degree of risk. The value of structured products depends not only on the performance of the underlying asset(s), but also on the credit rating of the issuer. Furthermore, the investor is exposed to the risk of default of the issuer/guarantor.

In respect of any product documentation, including key information documents of Packaged Retail and Insurance-based Investment Products ("KIDs") and key investor information documents of Undertakings for Collective Investment in Transferable Securities ("KIDs"), please note that these may change without notice. You should therefore ensure that you review the latest version of them prior to confirming to Pictet London your decision to invest. If you have been provided with a link to access the respective



KID/KIID/other product document, you should click on the link immediately before confirming to Pictet London Branch your decision to invest so that you can review the most recent version of the respective KID/KIID/other product document. If you have not been provided with a link to access the relevant document, or if you are in any doubt as to what the latest version of the respective KID/KIID/other product document is, or where it can be found, please ask your usual Pictet London Branch contact.

Pictet London Branch is not the manufacturer of the product(s), and the KID/KIID/other product document is provided by a third party. The KID/KIID/other product document is obtained from sources believed to be reliable. Pictet London Branch does not make any guarantee or warranty as to the correctness and accuracy of the data contained in the KID/KIID/other product document. Pictet London Branch may not be held liable for an investment decision or other transaction made based on reliance on, or use of, the data contained in the KID/KIID/other product document.

By subscribing to the product(s) proposed herein, you acknowledge that you have (i) received, in good time, read and understood any relevant documentation linked to the product(s), including, where applicable, the respective KID/KIID/other product document; (ii) taken note of the product(s) restrictions; and (iii) met the applicable subjective and objective eligibility conditions to invest in the product(s).

Pictet London Branch may, if necessary, rely on these acknowledgements and receive your orders to transmit them to another professional or to execute them, according to the relevant clauses of your mandate, as well as the Terms and Conditions of Pictet London Branch.

The content of this document may be read and/or used solely by its addressee. Any form of reproduction, copying, disclosure, modification and/or publication in any form or by any means whatsoever is not permitted without the prior written consent of Pictet London Branch, and no liability whatsoever will be incurred by Pictet London Branch. The addressee of this document agrees to comply with the applicable laws and regulations in the jurisdictions where they use the information provided in this document.

Pictet London Branch is a branch of Pictet & Cie (Europe) S.A.. Pictet & Cie (Europe) S.A. is a société anonyme (public limited liability company) incorporated in Luxembourg and registered with the Luxembourg Registre de Commerce et des Sociétés (RCS no. B32060). Its head office is at 15A, avenue J.F. Kennedy, L-2016 Luxembourg. Pictet London Branch is registered as a UK establishment with Companies House (establishment number BR016925) and its UK establishment office address is Stratton House 6th Floor, London, 5 Stratton Street, W1J 8LA.

Authorised and regulated by the Commission de Surveillance du Secteur Financier. Deemed authorised by the Prudential Regulation Authority. Subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details of the Temporary Permissions Regime, which allows EEA-based firms to operate in the UK for a limited period while seeking full authorisation, are available on the Financial Conduct Authority's website.

**Distributors**: Bank Pictet & Cie (Asia) Ltd ("BPCAL") in Singapore, 10 Marina Blvd #22-01 Tower 2, Marina Bay, Financial Centre, Singapore 018983 and Pictet & Cie (Europe) S.A., Hong Kong branch ("Pictet HK branch") in Hong Kong. The registered address of Pictet HK branch is 9/F, Chater House, 8 Connaught Road Central, Hong Kong.

The information, tools and material presented in this document are provided for information purposes only and are not to be used or considered as an offer, an invitation to offer or solicitation to buy, sell or subscribe for any securities, commodities, derivatives, (in respect of Singapore only) futures, or other financial instruments (collectively referred to as "Investments") or to enter into any legal relations, or as advice or recommendation with respect to any Investments. This document is intended for general circulation and is not directed at any particular person. This document does not have regard to the specific investment objectives, financial situation and/or the particular needs of any recipient of this document, laws should seek independent financial advice regarding the appropriateness of investing in any Investments or adopting any strategies discussed in this document, taking into account the specific investment objectives, financial situation or particular needs of the investor, before making a commitment to invest.

BPCAL/Pictet HK branch has not taken any steps to ensure that the Investments referred to in this document are suitable for any particular investor, and accepts no fiduciary duties to any investor in this regard. Furthermore, BPCAL/Pictet HK branch makes no representations and gives no advice concerning the appropriate accounting treatment or possible tax consequences of any Investment. Any investor interested in buying or making any Investment should conduct its own investigation and analysis of the Investment and consult its own professional adviser(s) about any Investment, including the risks involved with transactions on such Investment.

This document is not to be relied upon in substitution for the exercise of independent judgment. The value and income of any Investment mentioned in this document may fall as well as rise. The market value may be affected by, among other things, changes in economic, financial, political factors, time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Furthermore, foreign currency rates of exchange may have a positive or adverse effect on the value, price or income of any Investment mentioned in this document. Accordingly, investors must be willing and able to, and effectively assume all risks and may receive back less than originally invested.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, expressed or implied, is made by BPCAL/Pictet HK branch regarding future performance.

This document does not constitute the investment policy of BPCAL/Pictet HK branch, or an investment recommendation, and merely contains the different assumptions, views and analytical methods of the analysts who prepared them. Furthermore, the information, opinions and estimates expressed herein reflect a judgment at its original date of publication and are subject to change without notice and without any obligation on BPCAL/Pictet HK branch to update any of them. BPCAL/Pictet HK branch may have issued or distributed other reports or documents that are inconsistent with, and reach different conclusions from, the information presented in this document.

While the information and opinions presented herein are believed to be from sources considered to be reliable, BPCAL/Pictet HK branch is not able to and does not make any representation or warranty as to their accuracy or completeness. Accordingly, BPCAL/Pictet HK branch accepts no liability for any loss arising from the use of or reliance on this document, which is presented for information purposes only. BPCAL/Pictet HK branch reserves the right to act upon or use any of the information in this document at any time, including before its publication herein.

BPCAL/Pictet HK branch and its affiliates (or employees thereof) may or may not have long or short positions in, and buy or sell, or otherwise have interest in, any of the Investments mentioned herein, and may or may not have relationships with the issuers of or entities connected with Investments mentioned in this document. BPCAL/Pictet HK branch and their affiliates (or employees thereof) may act inconsistently with the information and/or opinions presented in this document.

The information used to prepare this document and/or any part of such information, may have been provided or circulated to employees and/or one or more clients of BPCAL/Pictet HK branch before this document was received by you and such information may have been acted upon by such recipients or by BPCAL/Pictet HK branch.

This document is provided solely for the information of the intended recipient and should not be reproduced, published, circulated or disclosed in whole or in part to any other person without the prior written consent of BPCAL/Pictet HK branch.



#### Singapore

This document is not directed to, or intended for distribution, publication to or use by, persons who are not accredited investors, expert investors or institutional investors as defined in section 4A of the Securities and Futures Act (Cap. 289 of Singapore) ("SFA") or any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject BPCAL and any of its affiliates or related corporations to any prospectus or registration requirements.

BPCAL has obtained an exemption from the Monetary Authority of Singapore ("MAS") under section 100(2) of the Financial Advisers Act ("FAA") for the provision of financial advisory services to High Net Worth Individuals (as defined in the MAS Guidelines on Exemption for Specialised Units Serving High Net Worth Individuals FAA-GO7) (the "Exemption") and is exempted from the requirements of sections 25, 27, 28 and 36 of the FAA, the MAS Notice on Recommendations on Investment Products (FAA-N16), MAS Notice on Appointment and Use of Introducers by Financial Advisers (FAA-N02), MAS Notice on Information to Clients and Product Information Disclosure (FAA-N03) and MAS Notice on Minimum Entry and Examination Requirements for Representatives of Licensed Financial Advisers and Exempt Financial Advisers (FAA-N13).

Please contact BPCAL in Singapore in respect of any matters arising from or in connection with this document.

#### Hong Kong

This document is not directed to, or intended for distribution, publication to or use by, persons who are not "professional investors" within the meaning of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder (the "SFO") or any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject Pictet HK branch and any of its affiliates or related corporations to any prospectus or registration requirements.

Pictet & Cie (Europe) S.A. is incorporated in Luxembourg with limited liability. It is an authorised institution within the meaning of the Banking Ordinance and a registered institution (CE No.: AQ515) under the SFO carrying on Type 1 (dealing in securities), Type 4 (advising on securities) and Type 9 (asset management) regulated activities.

Warning: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. Please contact Pictet HK branch in Hong Kong in respect of any matters arising from, or in connection with this document.

Distributor: Pictet Bank & Trust Limited, whose registered office is located at Building 1, Bayside Executive Park, West Bay Street & Blake Road, Nassau, New Providence, The Bahamas.

The document is not directed to, or intended for distribution or publication to or use by persons who are not Accredited Investors (as defined in the Securities Industry Regulations, 2012) and subject to the conditions set forth in the Securities Industry Regulations, 2012 or to any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject Pictet Bank & Trust Limited to any prospectus or registration requirements. Pictet Bank & Trust Limited is incorporated in The Bahamas with limited liability. It is a bank and trust company that is licensed in accordance with the Banks and Trust Companies' Regulation Act and is regulated by the Central Bank of The Bahamas. Additional ly, Pictet Bank & Trust Limited is registered with the Securities Commission of The Bahamas as a Broker Dealer II and is approved to (i) Deal in Securities 1.(a) & (c); (ii) Arrange Deals in securities; (iii) Manage Securities; (iv) Advise on Securities.

Warning: The content of this document has not been reviewed by any regulatory authority in The Bahamas. You are therefore advised to exercise caution when processing the information contained herein. If you are in any doubt about any of the content of this document, you should obtain independent professional advice.

